Harvard Bioscience Files 8-K on Financials
Ticker: HBIO · Form: 8-K · Filed: Nov 7, 2024 · CIK: 1123494
| Field | Detail |
|---|---|
| Company | Harvard Bioscience Inc (HBIO) |
| Form Type | 8-K |
| Filed Date | Nov 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: HBIO
TL;DR
Harvard Bioscience dropped an 8-K on Nov 7th detailing financial results and exhibits.
AI Summary
Harvard Bioscience, Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing provides an update on the company's financial performance and related disclosures.
Why It Matters
This 8-K filing provides crucial updates on Harvard Bioscience's financial health and operational results, which are important for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any unusual or significant risks.
Key Players & Entities
- HARVARD BIOSCIENCE, INC. (company) — Registrant
- November 7, 2024 (date) — Date of earliest event reported
- 84 October Hill Road (address) — Principal Executive Offices
- Holliston, MA 01746 (address) — Principal Executive Offices
- 001-33957 (identifier) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing for Harvard Bioscience, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, and to file Financial Statements and Exhibits.
On what date was this 8-K filing reported as of?
The filing was reported as of November 7, 2024.
What is Harvard Bioscience, Inc.'s principal executive office address?
The principal executive office address is 84 October Hill Road, Holliston, MA 01746.
What is Harvard Bioscience, Inc.'s telephone number?
The registrant's telephone number, including area code, is (508) 893-8999.
What is the Commission File Number for Harvard Bioscience, Inc.?
The Commission File Number for Harvard Bioscience, Inc. is 001-33957.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-11-07 07:02:04
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value HBIO The NASDAQ Stock Marke
Filing Documents
- f8k_110724.htm (8-K) — 24KB
- exh_991.htm (EX-99.1) — 194KB
- logo.jpg (GRAPHIC) — 9KB
- 0001171843-24-006086.txt ( ) — 426KB
- hbio-20241107.xsd (EX-101.SCH) — 3KB
- hbio-20241107_lab.xml (EX-101.LAB) — 33KB
- hbio-20241107_pre.xml (EX-101.PRE) — 22KB
- f8k_110724_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 7, 2024, Harvard Bioscience, Inc. (the "Company") issued a press release announcing financial results for the three months ended September 30, 2024, and the details of a related conference call to be held at 8:00 AM ET on November 7, 2024. The press release is furnished as Exhibit 99.1 and incorporated herein by reference. The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Harvard Bioscience, Inc. on November 7, 2024 104 Cover Page Interactive Data File (embedded within the XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARVARD BIOSCIENCE, INC. Date: November 7, 2024 By: /s/ Jennifer Cote Jennifer Cote Chief Financial Officer